Abstract Number: 906 • ACR/ARHP Annual Meeting 2016
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…Abstract Number: 1882 • ACR/ARHP Annual Meeting 2016
Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)
Background/Purpose: Eosinophilic fasciitis (EF) is a rare scleroderma-like disorder described in 1974 by Shulman. It is characterized by the acute onset of edema and induration…Abstract Number: 958 • ACR/ARHP Annual Meeting 2015
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…
ACR Meeting Abstracts